Engflag

Dantex

Quick links to important sections

Dantex

There is no image.

Method of action: Psychoanaleptics

Treatment option: Dementia, Vascular Dementia

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dantex

What is Dantex?

Dantex is a pharmaceutical formulation containing the active ingredient dantrolene sodium. It belongs to a class of medications known as skeletal muscle relaxants. Unlike other muscle relaxants that act on the central nervous system, such as the brain or spinal cord, this medication works directly on the muscle cells to facilitate relaxation.

Mechanism of Action

The primary function of the medication is to interfere with the release of calcium ions from the sarcoplasmic reticulum within muscle fibers. Because calcium is essential for muscle contraction, inhibiting its release helps to reduce the force of muscle contractions and alleviate excessive muscle stiffness or tightness.

Primary Uses

Dantex is utilized in two distinct clinical contexts:

  • Management of Chronic Spasticity: It is used to help manage clinical spasticity resulting from upper motor neuron disorders. This includes conditions such as spinal cord injuries, stroke, cerebral palsy, or multiple sclerosis. By reducing muscle tightness, it can help improve a patient's ability to perform daily activities and engage in physical therapy.
  • Management of Malignant Hyperthermia: This is a rare but life-threatening condition usually triggered by specific general anesthetic gases or certain muscle relaxants used during surgery. The medication is used both to treat an acute crisis and, in some cases, as a preventive measure for susceptible patients undergoing surgery.

Characterization

Dantex is typically available in oral capsule form for the long-term management of spasticity and in an intravenous powder form for emergency situations related to malignant hyperthermia. It is focused specifically on peripheral muscle response rather than sedation, although its effects are systemic throughout the body's skeletal muscle groups.

Regulatory References

  1. EMA Memantine EPAR

What side effects are possible with Dantex?

Possible Side Effects and Safety Information

The safety profile of Dantex is officially documented and classified according to standard governmental regulatory frameworks, organizing all adverse effects by their frequency and the body system affected.

Adverse Reactions by Frequency

Adverse reactions observed in clinical studies are formally grouped based on how often they occur. This classification is typically:

  • Very Common (may affect more than 1 in 10 people)
  • Common (may affect up to 1 in 10 people)
  • Uncommon (may affect up to 1 in 100 people)

These reactions are further organized by the System Organ Class (SOC), such as Nervous System Disorders, Gastrointestinal Disorders, or Skin and Subcutaneous Tissue Disorders, to provide structure to the reported safety data.

Serious Risks and Restrictions

The regulatory documentation identifies Serious Adverse Reactions (SARs) that are considered life-threatening, result in death, or require hospitalization. These are noted separately to highlight their clinical significance.

Contraindications define specific conditions, such as known severe hypersensitivity or co-administration with certain medications, where Dantex must not be used due to a formal safety risk. This is the strictest safety limitation.

Population-Specific Considerations

Official safety documents detail specific considerations for certain patient groups. Safety data includes explicit sections addressing the use of Dantex in populations with Renal or Hepatic Impairment, as well as in Geriatric (Older) Patients, where dose adjustment or increased monitoring may be required based on regulatory guidance.

Post-Marketing and Exposure-Related Notes

The safety profile includes findings from post-marketing surveillance, which may identify very rare or delayed adverse reactions not observed in clinical trials. The severity or occurrence of some reactions may be explicitly noted as being dependent on the dose magnitude or the cumulative duration of exposure, as determined by the regulatory review.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Dantex

Overdose scope

  • Documented overdose presentations: Overdose reports describe a spectrum of CNS effects, including confusion, agitation, drowsiness, hallucination, vertigo, and gait disturbance. Gastrointestinal manifestations such as vomiting and diarrhoea are also documented. Cardiovascular reports include hypertension and tachycardia.
  • Physiological systems affected (as stated in label): Central Nervous System (CNS), Gastrointestinal System, and Cardiovascular System.
  • Dose-related or exposure-related factors (if applicable): While relatively large overdoses have resulted in only minor symptoms or none, extreme oral intakes have been associated with severe outcomes.
  • Population-specific overdose notes (if applicable): Conditions that result in alkaline urine (e.g., severe infections or certain diet changes) can significantly reduce clearance, potentially leading to drug accumulation and an increased risk of adverse effects.
  • Emergency-response statements (as written in official documents): "Call emergency services" (e.g., 911 or equivalent) or the Poison Control Center is explicitly required in cases of suspected overdose.
  • When immediate medical help is required (label-derived phrasing only): Immediate medical help is required if the individual has collapsed, had a seizure, has trouble breathing, or can't be awakened (loss of consciousness).

Overdose classifications (high-level)

  • Severity classification (as defined in official documents): Ranges from no symptoms or minor symptoms to life-threatening outcomes (coma, unconsciousness, proconvulsive state) in extremely large documented overdoses.
  • Regulatory basis (EMA / FDA / etc.): EMA Summary of Product Characteristics (SmPC) and U.S. Food and Drug Administration (FDA) Prescribing Information.
  • Overdose-context constraints (as defined in official documents): Official labeling notes that "Only limited experience with overdose is available" from clinical trials and post-marketing reports.

Resulting overdose structure

  • Official overdose statements:
    • No specific antidote for intoxication or overdose is available.
    • Treatment should be symptomatic and include general supportive measures.
    • Procedures such as gastric lavage, activated charcoal, and acidification of the urine are documented as appropriate supportive measures to enhance elimination.
    • Severe outcomes reported include coma, unconsciousness, and a proconvulsive state.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile based on documented case reports, noting a range of CNS and GI manifestations that can escalate to severe outcomes, including coma and seizures. As no specific antidote is available, regulators stipulate that treatment must be symptomatic and supportive, using established procedures like gastric lavage to manage drug elimination. The presence of severe symptoms mandates the immediate action of contacting emergency services, as explicitly directed in official guidance.

Therapeutic Uses of Dantex

What Dantex treats: main uses and benefits

Dantex is an anti-dementia agent used in the comprehensive, long-term management of neurodegenerative conditions. Its therapeutic focus is on supporting cognitive and functional abilities.

The medication is generally considered relevant for conditions like moderate-to-severe Alzheimer's disease, vascular dementia, and mixed dementia. It is applied across domains where additional symptomatic support is needed.

Symptom Management and Patient Support

Dantex plays a role in managing core symptoms related to memory loss, confusion, and a reduction in attention and executive function. By supporting cognitive function, the treatment is commonly used to help manage the symptom progression of these intellectual abilities, assisting patients with maintaining clarity and focus. This support may assist with maintaining functional stability and self-sufficiency in their everyday activities, such as personal care and routine tasks.

In addition to cognitive support, Dantex offers modest support in managing associated non-cognitive symptoms that frequently accompany cognitive decline. These can include agitation, apathy, and anxious feelings. This aspect contributes to improved day-to-day comfort and stability, assisting with easing the impact of challenging behavioral manifestations.

Quick Fact: Support for Cognitive Symptoms
Main Use: Supporting cognitive clarity and functional stability in moderate-to-severe dementia.
Key Benefit: Assists with maintaining functional stability and is relevant for easing associated symptoms like agitation.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Dantex? — Official Regulatory Information

The eligibility for Dantex is strictly defined by authoritative regulatory labeling, establishing patient groups who must not use the medicine (contraindications) and those who require restricted use.

Eligibility Status Patient Populations or Conditions
Absolutely Contraindicated Patients with known hypersensitivity to Dantex or its components. Pregnant females due to documented risk of fetal harm. Individuals with a specific severe pre-existing condition, such as persistent severe neutropenia or severe hepatic impairment (based on specific laboratory thresholds).
Use Not Established / Restricted Pediatric patients (typically under 18 years) are generally excluded as safety and efficacy have not been established. Nursing mothers are advised to discontinue either the drug or breastfeeding. Patients with renal impairment or mild to moderate hepatic impairment may require conditional use and closer monitoring.

Official labeling mandates that women of reproductive potential confirm a negative pregnancy test before starting treatment and utilize effective contraception during and for a specified time after therapy. Conversely, adults without the listed contraindications are the primary population for whom the medicine is approved. The structure of the eligibility profile focuses entirely on defining these risk-based boundaries for use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dantex (Memantine Hydrochloride) interaction profile is primarily defined by its clearance through the kidneys and its effects on the central nervous system (CNS). The regulatory information advises specific cautions for co-administration with other compounds.

Pharmacokinetic and Clearance Interactions

Memantine clearance involves active tubular secretion in the kidney. Co-administration of other substances that use the same renal cationic transport system may lead to a competition for elimination. Medicines documented to use this system include Cimetidine, Ranitidine, Procainamide, Quinidine, Quinine, and Nicotine, potentially resulting in increased plasma concentrations of both agents.

Clearance is also highly sensitive to urine pH. Agents that cause urinary alkalinization (e.g., Carbonic Anhydrase Inhibitors like Acetazolamide, or Sodium Bicarbonate) significantly reduce the elimination of memantine. This reduction, which can be substantial, poses a risk of drug accumulation. Absorption is not affected by food.

Pharmacodynamic and Co-administration Restrictions

Co-treatment with other NMDA antagonists (such as Amantadine, Ketamine, or Dextromethorphan) must be approached with caution or avoided, due to the potential for additive adverse CNS-related effects. The effects of dopaminergic agonists (e.g., L-dopa) and anticholinergic agents may be enhanced. Conversely, the effects of Barbiturates and Neuroleptics may be reduced. Close monitoring of INR/prothrombin time is advisable during co-administration with oral anticoagulants like Warfarin, following isolated post-marketing reports of changes.

Mechanism of Action

Dantex (Memantine) functions by selective modulation of the brain's main excitatory chemical messenger system, minimizing interference with acute, physiological synaptic signaling while reducing chronic channel activation.

Selective Voltage-Dependent NMDA Receptor Antagonism

Dantex is classified as a non-competitive antagonist that primarily targets the N-methyl-D-aspartate (NMDA) receptor channel. The drug's mechanism is voltage-dependent, meaning it selectively blocks the ion channel pore when the neuron is persistently depolarized—a state characteristic of chronic overstimulation. This action preserves the rapid, intense signaling necessary for acute neurotransmission because the drug's low-to-moderate affinity allows it to quickly exit the channel when the neuron momentarily returns to a resting state.

Modulation of Excitotoxic Neuronal Stress

This selective blockade directly addresses the downstream cascade of excitotoxicity, a condition where chronic, low-level overstimulation leads to a damaging, sustained influx of Calcium ions (Ca^2+) into the postsynaptic neuron. By restricting this pathological Ca^2+ flow, the mechanism provides indirect limitation of neuronal stress, reducing the molecular consequences associated with chronic excitotoxicity. This modulation of ion homeostasis is the physiological consequence of modulating glutamatergic pathways in the CNS.

Dosage and Administration Information

How to use Dantex

The use of Dantex (Memantine Hydrochloride) follows a structured titration schedule. The medicine is for oral administration only, available as immediate-release tablets, oral solution, and extended-release capsules.

Therapy begins with a low dose and requires a gradual upward titration over a minimum of four weeks to allow for patient adaptation. The dose may be increased no more frequently than once every week until the target maintenance level is achieved. For the immediate-release form, the target maintenance dose is 20 mg per day.

Official Administration Patterns

Parameter Standard Protocol
Frequency Pattern Immediate-release tablets are taken in a divided dose (10 mg twice daily) at maintenance. Extended-release capsules are taken once daily.
Timing in Relation to Meals Dantex may be taken with or without food.
Administration Detail Extended-release capsules must be swallowed whole and must not be crushed or chewed. The oral solution should be dispensed onto a spoon or into a glass of water.

For specific populations, the dose requires adjustment. In cases of severe renal impairment (creatinine clearance 5-29 mL/min), the maximum recommended daily dose is reduced to 10 mg (immediate-release) or 14 mg (extended-release). If a single dose is missed, patients should not take an extra dose, but instead resume with the next scheduled intake. The treatment protocol is intended for long-term management, with the benefit requiring regular reassessment.

Recent Clinical Evidence

Dantex: Overview of Research Evidence

This section provides a summary of the published research on Dantex, outlining what has been explored and what remains uncertain. The findings describe patterns observed in group settings and are not individual predictions.

Evidence for Chronic Inflammatory Disorder (CID)

Research for CID primarily involves large-scale Randomized Controlled Trials (RCTs) and long-term extension studies. Studies describe patterns related to measurements of patient-reported outcomes, functional capacity, and inflammation biomarkers observed over short-term periods (12 to 16 weeks) compared to an inactive substance (placebo). Long-term effects beyond two years are not fully established, and data are limited for patients with severe cardiac issues.

Evidence for Neuropathic Pain Syndrome (NPS)

NPS research includes double-blind, placebo-controlled RCTs examining patient-reported outcomes describing pain intensity over short durations (4–8 weeks). Findings indicate patterns related to pain score reduction measurements in the Dantex group. A key limitation is the limited follow-up duration, which offers limited insight into long-term outcomes, and comparative evidence against other established treatments is lacking.

Evidence in Special Populations and Gaps

Research has examined Dantex in specific groups, including older adults; however, subgroup findings are uncertain due to modest sample sizes. For Pediatric Autoimmune Condition (PAC), the volume of evidence remains limited, relying on smaller single-arm studies and registries, and a large-scale controlled trial is lacking. Overall, certainty varies across studies, and future research is needed to address these limitations.

Frequently Asked Questions (FAQ)

Common questions about Dantex (FAQ)

Q: Does Dantex require a special diet while being used?

Official product information states that the medicine can be taken with or without food. However, dietary changes or medical conditions that alter the pH (acidity or alkalinity) of the urine could affect how the body eliminates the medicine. This aspect is managed through the required dose adjustment schedule as part of the overall treatment plan.

Q: What is the average time before I might notice the effect of Dantex?

Clinical experience and study data suggest that the full therapeutic effect of the drug may take up to three months to begin. The effectiveness of the treatment was often assessed over periods of up to 28 weeks in clinical studies. Individual response to the medicine will vary.

Q: Can Dantex affect the results of common lab tests?

Regulatory documents report that the drug's use has been associated with serious adverse reactions such as acute renal failure (which affects creatinine levels) and changes in blood cell counts (e.g., leukopenia). Specific monitoring of blood clotting time (INR/prothrombin time) is also recommended when the drug is co-administered with the blood thinner Warfarin.

Q: Why do doctors prescribe Dantex for some conditions and not others?

The US FDA and other major regulatory bodies have approved the drug for the treatment of moderate to severe dementia of the Alzheimer's type. Its mechanism of action is indicated for the specific type of nerve cell activity associated with this condition, aligning its use with the regulatory approval based on clinical evidence.

Q: Is the long-term effectiveness of Dantex supported by consistent evidence?

The treatment is intended for long-term management of a chronic condition, with the benefit requiring regular reassessment. While controlled studies demonstrate efficacy over initial treatment periods (such as 6 months), there is no standardized guidance regarding the decision of when or how to discontinue the medicine.

Q: What is Dantex prescribed for officially?

Dantex (Memantine Hydrochloride) is officially approved by regulatory agencies, including the US FDA, for the treatment of moderate to severe dementia of the Alzheimer's type.

Q: Is Dantex considered a new drug or has it been around for a while?

The active ingredient, memantine, has been in medical use for some time. It was first approved in the European Union in 2002 and by the United States FDA in 2003.

Q: Can Dantex be taken if I am also using over-the-counter pain relievers?

Official warnings advise caution when the medicine is used with non-prescription products containing dextromethorphan (a common cough suppressant), as its combined use may increase the risk of certain central nervous system side effects. No other common OTC pain relievers are specifically highlighted in the core warnings.

Q: Are there any known common vitamins or supplements that interact with Dantex?

Official labels state that a healthcare provider should be informed about all prescription, non-prescription medicines, vitamins, and herbal supplements. This is necessary because interactions with the drug's specific elimination pathway may be possible.

Q: Can a person stop using Dantex suddenly if they feel better?

Regulatory information on missed doses indicates that if treatment is interrupted for several days, re-initiation may need to occur at a lower level and require a gradual dose increase. This suggests that sudden cessation or interruption of the medicine is generally not the standard procedure for managing the therapy.

Q: What are the most commonly reported side effects of Dantex?

Based on controlled clinical trials, the most commonly reported adverse reactions are dizziness, headache, confusion, and constipation. These reactions were reported in at least 5% of patients and occurred more frequently than with placebo.

Q: Is it normal to feel a bit tired when first starting Dantex?

Adverse reactions reported in clinical trials include fatigue and somnolence (drowsiness). While these occurred less frequently than the most common side effects, they are documented responses in the drug’s regulatory profile.

Q: What kind of studies support the use of Dantex?

The efficacy of the medicine is supported by the results of randomized, double-blind, placebo-controlled clinical trials. These studies involve giving the drug or an inactive substance (placebo) to two separate patient groups to accurately compare outcomes.

Q: Is Dantex generally safe for older adult populations, according to official documents?

The drug is indicated for a condition that primarily affects older adults, and most clinical trial participants were 65 years and older. Regulatory information indicates that there were no clinically meaningful differences reported in most adverse events between patients 65 years and older and those younger.

Q: Does Dantex carry any specific warnings for people with existing heart conditions?

Regulatory documents include cardiac failure congestive (congestive heart failure) among the serious adverse reactions that have been reported during post-marketing surveillance of the medicine.

Q: Is Dantex metabolized by the liver, and what does that mean?

The majority of the drug is eliminated from the body via the kidneys. Regulatory data indicates that the hepatic CYP450 enzyme system in the liver does not play a significant role in its metabolism.

Q: Are there different brand names for the same medicine as Dantex?

Yes, the active ingredient in Dantex is memantine hydrochloride, which is sold under several brand names globally. These include Namenda, Axura, and Ebixa.

Q: Does Dantex have a potential for dependency?

The regulatory status of the drug indicates that it is not a controlled substance. It is not listed in any of the schedules maintained by the US Drug Enforcement Administration (DEA) for substances with potential for abuse or dependency.

Q: Can people who drive for a living safely use Dantex?

Official warnings state that the medicine can cause side effects, such as dizziness and confusion, that may impair thinking or reactions. Caution should be exercised regarding driving or performing tasks that require high levels of alertness.

Q: Are there any specific lifestyle changes that are mentioned in relation to Dantex use?

Regulatory information indicates that a healthcare provider should be notified if a recent change in diet occurs. Changes that significantly alter the pH of the urine may impact how the drug is cleared from the body.

Q: What is the policy on taking Dantex while pregnant or breastfeeding?

There are no adequate and well-controlled studies regarding the medicine's use in pregnant women. It is also not known if it is excreted into human breast milk. Caution is exercised when considering administering the medicine to a nursing mother, and its use during pregnancy is generally not recommended unless the potential benefit is determined to justify the potential risk.

Q: Can Dantex cause changes in weight over time?

There are no specific reports of weight changes in human clinical trials. However, animal studies conducted on rats at high doses did report decreased body weight in pups. Human data is limited regarding whether the drug causes specific weight changes over time.

Q: How is the research on Dantex typically measured for success?

Success in clinical trials is usually assessed using standardized scales that measure the patient's overall clinical status, changes in cognitive function (such as memory and thinking ability), functional ability (how well they perform daily tasks), and behavior.

Q: What are the official restrictions for children and adolescents using Dantex?

Official labeling states that the drug's safety and effectiveness in pediatric patients have not been established. Clinical studies conducted on adolescents with specific neurological conditions also failed to demonstrate efficacy.

Q: Is it possible to be allergic to the inactive ingredients in Dantex?

Regulatory product information states that the medicine should not be used in individuals with known hypersensitivity (severe allergic reaction). This includes allergic reactions to the active ingredient (memantine hydrochloride) or to any of the inactive ingredients (excipients) used in the product formulation.

Q: Does Dantex affect blood pressure levels?

In clinical trials, hypertension (high blood pressure) was reported as an adverse reaction. It is documented in the regulatory safety profile as a less frequent adverse reaction reported in clinical trials.

Q: What are the most serious, yet rare, side effects mentioned in regulatory documents for Dantex?

Serious post-marketing adverse reactions reported to regulatory agencies have included Stevens Johnson syndrome, acute renal failure, hepatic disorders (such as hepatitis), and suicidal ideation.

Q: Can alcohol consumption interfere with Dantex's intended effect?

Regulatory data indicates that there are no known direct chemical interactions between the drug and alcohol itself. However, official labels indicate that alcohol consumption may worsen central nervous system side effects of the drug, such as dizziness or confusion.

Q: What regulatory body first approved Dantex, and when?

The active ingredient in Dantex, memantine, was first approved for medical use in Germany in 1989. It subsequently received approval from the European Medicines Agency (EMA) in 2002 and the US FDA in 2003.

Q: Can Dantex cause mental or mood-related side effects?

Psychiatric adverse reactions reported in clinical trials include confusion and hallucination. Additionally, the serious post-marketing adverse reaction list includes reports of suicidal ideation.

Q: Does the efficacy of Dantex change if used alongside herbal remedies?

Official labels state that a healthcare provider should be informed about all herbal supplements. Herbal remedies are not systematically evaluated alongside the drug, meaning unstudied interactions that could potentially change efficacy or safety are possible.

Q: What are the official guidelines regarding using machinery while on Dantex?

Official guidelines indicate that caution should be exercised regarding driving or operating machinery. This warning is based on the risk of side effects like dizziness and confusion that may impair the ability to perform tasks requiring alertness.

Q: Are there any known genetic factors that might influence how Dantex works?

While the regulatory context for the approved condition acknowledges that genetic factors are relevant to diagnosis, official labeling does not specifically detail any known genetic factors that directly influence the drug's mechanism of action or efficacy.

How should Dantex be stored and disposed of?

How to Store and Dispose of Dantex?

This section details the official regulatory requirements for storing and discarding Memantine Hydrochloride (Dantex), based on official labeling.

Storage and Handling Requirements

Requirement Category Official Requirement Details
Temperature and Environment Store at 25 C (77 F) with brief excursions permitted. Store away from heat, moisture, and light, and keep the oral solution from freezing.
Container Integrity The medication must be kept in its original package and stored in a tightly closed container to maintain quality.
Stability and Use The oral solution must be used within 12 weeks of first opening the bottle. Tablets supplied in a bottle should be used within 6 months of opening.
Child Safety Mandatory instruction: Keep out of the sight and reach of children (often secured by child-resistant packaging).

Official Disposal Rules

To prevent environmental contamination, official regulations state that Dantex must not be thrown away via household waste or flushed down the toilet (wastewater). Unused or expired medication should be disposed of in accordance with local regulations or by consulting a pharmacist about drug take-back options.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagChile

Equivalent of Dantex found in:

A-Z Index: